In its first part, this e-presentation explains how barriers to biosimilars can have an impact on access to affordable medicines and public health expenditure. In its second part, it explores the consequences of unjustly granted preliminary injunctions in patent litigation cases in the light of a recent ruling from the CJEU (C-688/17, Bayer vs Richter) and an interim decision adopted in the Netherland.
e-Presentation | March 2021 | Learning time: 41 minutes
Marleen van den Horst, Partner, BarentsKrans Coöperatief Advocaten, The Hague.